agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Company profile
Ticker
AGEN
Exchange
Website
CEO
Garo Armen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANTIGENICS INC /DE/
SEC CIK
Corporate docs
IRS number
61562417
AGEN stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
5 Apr 24
EFFECT
Notice of effectiveness
19 Mar 24
S-8
Registration of securities for employees
15 Mar 24
POS AM
Prospectus update (post-effective amendment)
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
POSASR
Automatic shelf registration (post-effective amendment)
14 Mar 24
8-K
Agenus Reports Fourth Quarter and Full Year 2023 Results
14 Mar 24
DEFA14A
Additional proxy soliciting materials
29 Feb 24
DEF 14A
Definitive proxy
26 Feb 24
PRE 14A
Preliminary proxy
15 Feb 24
Transcripts
AGEN
Earnings call transcript
2023 Q4
14 Mar 24
AGEN
Earnings call transcript
2023 Q3
7 Nov 23
AGEN
Earnings call transcript
2023 Q1
9 May 23
AGEN
Earnings call transcript
2022 Q4
14 Mar 23
AGEN
Earnings call transcript
2022 Q3
8 Nov 22
AGEN
Earnings call transcript
2022 Q2
9 Aug 22
AGEN
Earnings call transcript
2022 Q1
10 May 22
AGEN
Earnings call transcript
2021 Q4
1 Mar 22
AGEN
Earnings call transcript
2021 Q3
9 Nov 21
AGEN
Earnings call transcript
2021 Q2
9 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 109.97 mm | 109.97 mm | 109.97 mm | 109.97 mm | 109.97 mm | 109.97 mm |
Cash burn (monthly) | 11.97 mm | 8.42 mm | 15.45 mm | 17.76 mm | 21.74 mm | 19.26 mm |
Cash used (since last report) | 79.57 mm | 55.99 mm | 102.71 mm | 118.08 mm | 144.57 mm | 128.07 mm |
Cash remaining | 30.41 mm | 53.98 mm | 7.27 mm | -8.10 mm | -34.60 mm | -18.10 mm |
Runway (months of cash) | 2.5 | 6.4 | 0.5 | -0.5 | -1.6 | -0.9 |
Institutional ownership, Q4 2023
46.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 21 |
Closed positions | 59 |
Increased positions | 40 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 100.77 bn |
Total shares | 195.17 mm |
Total puts | 0.00 |
Total calls | 1.70 mm |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Deep Track Capital | 31.70 mm | $26.24 bn |
Vanguard | 30.27 mm | $25.06 bn |
Sofinnova Investments | 15.66 mm | $12.96 bn |
Artal | 15.63 mm | $12.94 mm |
Artal International S.C.A. | 15.63 mm | $0.00 |
INCY Incyte | 12.07 mm | $38.87 mm |
GILD Gilead Sciences | 11.11 mm | $35.78 mm |
STT State Street | 8.68 mm | $7.19 bn |
Larry N Feinberg | 8.42 mm | $27.10 mm |
Renaissance Technologies | 6.03 mm | $5.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Armen Garo H | Common Stock | Grant | Acquire A | No | No | 0.5 | 32,697 | 16.35 k | 1,335,325 |
1 Apr 24 | Wright Timothy | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 14,134.924 | 0.00 | 192,858.238 |
1 Apr 24 | Susan B Hirsch | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 32,039.161 | 0.00 | 95,791.152 |
1 Apr 24 | Wiinberg Ulf | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 38,635.459 | 0.00 | 279,121.341 |
22 Mar 24 | Armen Garo H | Common Stock | Grant | Acquire A | No | No | 0.55 | 27,163 | 14.94 k | 1,302,628 |
News
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
12 Apr 24
Agenus Announces Updated Phase 1 Data and Progress On BOT/BAL Development In Metastatic MSS Colorectal Cancer, Updated Phase 1 Data Demonstrate 12-Month Overall Survival (OS) Of 71% And 18-Month OS Of 62%
12 Apr 24
Gold Moves Higher; Auddia Shares Surge
8 Apr 24
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
8 Apr 24
Press releases
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
12 Apr 24
Agenus Announces Reverse Stock Split of Common Stock
5 Apr 24
Agenus Reports Fourth Quarter and Full Year 2023 Results
14 Mar 24
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
6 Mar 24
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Mar 24